Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Article
  • Published:

Epigallocatechin-3-gallate (EGCG) attenuates inflammation in MRL/lpr mouse mesangial cells

Cellular & Molecular Immunology volume 7, pages 123–132 (2010)Cite this article

Abstract

Epigallocatechin-3-gallate (EGCG), a bioactive component of green tea, has been reported to exert anti-inflammatory effects on immune cells. EGCG is also shown to activate the metabolic regulator, adenosine 5'-monophosphate-activated protein kinase (AMPK). Reports have also indicated that EGCG inhibits the immune-stimulated phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway. The PI3K/Akt/mTOR pathway has been implicated in mesangial cell activation in lupus. Mesangial cells from MRL/lpr lupus-like mice are hyper-responsive to immune stimulation and overproduce nitric oxide (NO) and other inflammatory mediators when stimulated. In our current studies, we sought to determine the mechanism by which EGCG attenuates immune-induced expression of pro-inflammatory mediators. Cultured mesangial cells from MRL/lpr mice were pre-treated with various concentrations of EGCG and stimulated with lipopolysaccharide (LPS)/interferon (IFN)-γ. EGCG activated AMPK and blocked LPS/IFN-γ-induced inflammatory mediator production (iNOS expression, supernatant NO and interleukin-6). Interestingly, EGCG attenuated inflammation during AMPK inhibition indicating that the anti-inflammatory effect of EGCG may be partially independent of AMPK activation. Furthermore, we found that EGCG effectively inhibited the immune-stimulated PI3K/Akt/mTOR pathway independently of AMPK, by decreasing phosphorylation of Akt, suggesting an alternate mechanism for EGCG-mediated anti-inflammatory action in mesangial cells. Taken together, these studies show that EGCG attenuated inflammation in MRL/lpr mouse mesangial cells via the PI3K/Akt/mTOR pathway. Our findings suggest a potential therapeutic role for the use of EGCG to regulate inflammation and control autoimmune disease.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  1. Fessel WJ . Epidemiology of systemic lupus erythematosus. Rheum Dis Clin North Am 1988; 14: 15–23.

    CAS  PubMed  Google Scholar 

  2. Le Marchand L . Cancer preventive effects of flavonoids – a review. Biomed Pharmacother 2002; 56: 296–301.

    Article  CAS  PubMed  Google Scholar 

  3. Farabegoli F, Barbi C, Lambertini E, Piva R . (−)-Epigallocatechin-3-gallate downregulates estrogen receptor alpha function in MCF-7 breast carcinoma cells. Cancer Detect Prev 2007; 31: 499–504.

    Article  CAS  PubMed  Google Scholar 

  4. Shankar S, Ganapathy S, Hingorani SR, Srivastava RK . EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer. Front Biosci 2008; 13: 440–452.

    Article  PubMed  Google Scholar 

  5. Wolfram S, Raederstorff D, Preller M, Wang Y, Teixeira SR, Riegger C et al. Epigallocatechin gallate supplementation alleviates diabetes in rodents. J Nutr 2006; 136: 2512–2518.

    Article  CAS  PubMed  Google Scholar 

  6. Singh R, Ahmed S, Malemud CJ, Goldberg VM, Haqqi TM . Epigallocatechin-3-gallate selectively inhibits interleukin-1beta-induced activation of mitogen activated protein kinase subgroup c-Jun N-terminal kinase in human osteoarthritis chondrocytes. J Orthop Res 2003; 21: 102–109.

    Article  CAS  PubMed  Google Scholar 

  7. Ahmed S, Rahman A, Hasnain A, Lalonde M, Goldberg VM, Haqqi TM . Green tea polyphenol epigallocatechin-3-gallate inhibits the IL-1 beta-induced activity and expression of cyclooxygenase-2 and nitric oxide synthase-2 in human chondrocytes. Free Radic Biol Med 2002; 33: 1097–1105.

    Article  CAS  PubMed  Google Scholar 

  8. Singh R, Ahmed S, Islam N, Goldberg VM, Haqqi TM . Epigallocatechin-3-gallate inhibits interleukin-1beta-induced expression of nitric oxide synthase and production of nitric oxide in human chondrocytes: suppression of nuclear factor kappaB activation by degradation of the inhibitor of nuclear factor kappaB. Arthritis Rheum 2002; 46: 2079–2086.

    Article  CAS  PubMed  Google Scholar 

  9. Fu Y, Koo MW . EGCG protects HT-22 cells against glutamate-induced oxidative stress. Neurotox Res 2006; 10: 23–30.

    Article  CAS  PubMed  Google Scholar 

  10. Nishikawa H, Wakano K, Kitani S . Inhibition of NADPH oxidase subunits translocation by tea catechin EGCG in mast cell. Biochem Biophys Res Commun 2007; 362: 504–509.

    Article  CAS  PubMed  Google Scholar 

  11. Wolfram S, Wang Y, Thielecke F . Anti-obesity effects of green tea: from bedside to bench. Mol Nutr Food Res 2006; 50: 176–187.

    Article  CAS  PubMed  Google Scholar 

  12. Wu CH, Wu CF, Huang HW, Jao YC, Yen GC . Naturally occurring flavonoids attenuate high glucose-induced expression of proinflammatory cytokines in human monocytic THP-1 cells. Mol Nutr Food Res 2009; 53: 984–995.

    Article  CAS  PubMed  Google Scholar 

  13. Bae H-B, Li M, Kim J-P, Kim S-J, Jeong C-W, Lee H-G et al. The effect of epigallocatechin gallate on lipopolysaccharide-induced acute lung injury in a murine model. Inflammation 2009; in press.

  14. Zhu J, Wang O, Ruan L, Hou X, Cui Y, Wang JM et al. The green tea polyphenol (−)-epigallocatechin-3-gallate inhibits leukocyte activation by bacterial formylpeptide through the receptor FPR. Int Immunopharmacol 2009; 9: 1126–1130.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Hwang JT, Ha J, Park IJ, Lee SK, Baik HW, Kim YM et al. Apoptotic effect of EGCG in HT-29 colon cancer cells via AMPK signal pathway. Cancer Lett 2007; 247: 115–121.

    Article  CAS  PubMed  Google Scholar 

  16. Jeong HW, Hsu KC, Lee JW, Ham M, Huh JY, Shin HJ et al. Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am J Physiol Endocrinol Metab 2009; 296: E955–E964.

    Article  CAS  PubMed  Google Scholar 

  17. Sag D, Carling D, Stout RD, Suttles J . Adenosine 5'-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J Immunol 2008; 181: 8633–8641.

    Article  CAS  PubMed  Google Scholar 

  18. Theofilopoulos AN, Dixon FJ . Murine models of systemic lupus erythematosus. Adv Immunol 1985; 37: 269–390.

    Article  CAS  PubMed  Google Scholar 

  19. Theofilopoulos AN, Kono DH . Mechanisms and genetics of autoimmunity. Ann N Y Acad Sci 1998; 841: 225–235.

    Article  CAS  PubMed  Google Scholar 

  20. Cook HT, Smith J, Salmon JA, Cattell V . Functional characteristics of macrophages in glomerulonephritis in the rat. O2-generation, MHC class II expression, and eicosanoid synthesis. Am J Pathol 1989; 134: 431–437.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Reilly CM, Oates JC, Sudian J, Crosby MB, Halushka PV, Gilkeson GS . Prostaglandin J(2) inhibition of mesangial cell iNOS expression. Clin Immunol 2001; 98: 337–345.

    Article  CAS  PubMed  Google Scholar 

  22. Zhou Y, Ling E, Dheen S . Dexamethasone suppresses monocyte chemoattractant protein-1 production via mitogen activated protein kinase phosphatase-1 dependent inhibition of Jun N-terminal kinase and p38 mitogen-activated protein kinase in activated rat microglia. J Neurochem 2007; 102: 667–678.

    Article  CAS  PubMed  Google Scholar 

  23. Reilly CM, Farrelly LW, Viti D, Redmond ST, Hutchison F, Ruiz P et al. Modulation of renal disease in MRL/lpr mice by pharmacologic inhibition of inducible nitric oxide synthase. Kidney Int 2002; 61: 839–846.

    Article  CAS  PubMed  Google Scholar 

  24. Bollain-y-Goytia JJ, Ramirez-Sandoval R, Daza L, Esparza E, Barbosa O, Ramirez D et al. Widespread expression of inducible NOS and citrulline in lupus nephritis tissues. Inflamm Res 2009; 58: 61–66.

    Article  CAS  PubMed  Google Scholar 

  25. Oates JC, Shaftman SR, Self SE, Gilkeson GS . Association of serum nitrate and nitrite levels with longitudinal assessments of disease activity and damage in systemic lupus erythematosus and lupus nephritis. Arthritis Rheum 2008; 58: 263–272.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Kashem A, Endoh M, Yano N, Yamauchi F, Nomoto Y, Sakai H . Expression of inducible-NOS in human glomerulonephritis: the possible source is infiltrating monocytes/macrophages. Kidney Int 1996; 50: 392–399.

    Article  CAS  PubMed  Google Scholar 

  27. Reilly CM, Mishra N, Miller JM, Joshi D, Ruiz P, Richon VM et al. Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. J Immunol 2004; 173: 4171–4178.

    Article  CAS  PubMed  Google Scholar 

  28. Gilkeson G, Cannon C, Oates J, Reilly C, Goldman D, Petri M . Correlation of serum measures of nitric oxide production with lupus disease activity. J Rheumatol 1999; 26: 318–324.

    CAS  PubMed  Google Scholar 

  29. Vermes I, Haanen C, Steffens-Nakken H, Reutellingsperger. A novel assay for apoptosis Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995; 184: 39–51.

    Article  CAS  PubMed  Google Scholar 

  30. Peairs A, Radjavi A, Davis S, Li L, Ahmed A, Giri S et al. Activation of AMPK inhibits inflammation in MRL/lpr mouse mesangial cells. Clin Exp Immunol 2009; 156: 542–551.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Collins QF, Liu HY, Pi J, Liu Z, Quon MJ, Cao W . Epigallocatechin-3-gallate (EGCG), a green tea polyphenol, suppresses hepatic gluconeogenesis through 5'-AMP-activated protein kinase. J Biol Chem 2007; 282: 30143–30149.

    Article  CAS  PubMed  Google Scholar 

  32. Moon HS, Chung CS, Lee HG, Kim TG, Choi YJ, Cho CS . Inhibitory effect of (−)-epigallocatechin-3-gallate on lipid accumulation of 3T3-L1 cells. Obesity (Silver Spring) 2007; 15: 2571–2582.

    Article  CAS  Google Scholar 

  33. Oh JH, Lee TJ, Park JW, Kwon TK . Withaferin A inhibits iNOS expression and nitric oxide production by Akt inactivation and down-regulating LPS-induced activity of NF-kappaB in RAW 264.7 cells. Eur J Pharmacol 2008; 599: 11–17.

    Article  CAS  PubMed  Google Scholar 

  34. Jung CH, Jung H, Shin YC, Park JH, Jun CY, Kim HM et al. Eleutherococcus senticosus extract attenuates LPS-induced iNOS expression through the inhibition of Akt and JNK pathways in murine macrophage. J Ethnopharmacol 2007; 113: 183–187.

    Article  CAS  PubMed  Google Scholar 

  35. Sheu ML, Chao KF, Sung YJ, Lin WW, Lin-Shiau SY, Liu SH . Activation of phosphoinositide 3-kinase in response to inflammation and nitric oxide leads to the up-regulation of cyclooxygenase-2 expression and subsequent cell proliferation in mesangial cells. Cell Signal 2005; 17: 975–984.

    Article  CAS  PubMed  Google Scholar 

  36. Lim HK, Choi YA, Park W, Lee T, Ryu SH, Kim SY et al. Phosphatidic acid regulates systemic inflammatory responses by modulating the Akt-mammalian target of rapamycin-p70S6 kinase 1 pathway. J Biol Chem 2003; 278: 45117–45127.

    Article  CAS  PubMed  Google Scholar 

  37. Cao W, Manicassamy S, Tang H, Kasturi SP, Pirani A, Murthy N et al. Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway. Nat Immunol 2008; 9: 1157–1164.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Park IJ, Lee YK, Hwang JT, Kwon DY, Ha J, Park OJ . Green tea catechin controls apoptosis in colon cancer cells by attenuation of H2O2-stimulated COX-2 expression via the AMPK signaling pathway at low-dose H2O2 . Ann NY Acad Sci 2009; 1171: 538–544.

    Article  CAS  PubMed  Google Scholar 

  39. Schulz E, Anter E, Zou MH, Keaney JF Jr . Estradiol-mediated endothelial nitric oxide synthase association with heat shock protein 90 requires adenosine monophosphate-dependent protein kinase. Circulation 2005; 111: 3473–3480.

    Article  CAS  PubMed  Google Scholar 

  40. Huang CH, Tsai SJ, Wang YJ, Pan MH, Kao JY, Way TD . EGCG inhibits protein synthesis, lipogenesis, and cell cycle progression through activation of AMPK in p53 positive and negative human hepatoma cells. Mol Nutr Food Res 2009; 53: 1156–1165.

    Article  CAS  PubMed  Google Scholar 

  41. Murase T, Misawa K, Haramizu S, Hase T . Catechin-induced activation of the LKB1/AMP-activated protein kinase pathway. Biochem Pharmacol 2009; 78: 78–84.

    Article  CAS  PubMed  Google Scholar 

  42. De Vera ME, Taylor BS, Wang Q, Shapiro RA, Billiar TR, Geller DA . Dexamethasone suppresses iNOS gene expression by upregulating I-kappa B alpha and inhibiting NF-kappa B. Am J Physiol 1997; 273: G1290–G1296.

    Article  CAS  PubMed  Google Scholar 

  43. Grassl C, Luckow B, Schlondorff D, Dendorfer U . Transcriptional regulation of the interleukin-6 gene in mesangial cells. J Am Soc Nephrol 1999; 10: 1466–1477.

    CAS  PubMed  Google Scholar 

  44. Eberhardt W, Pluss C, Hummel R, Pfeilschifter J . Molecular mechanisms of inducible nitric oxide synthase gene expression by IL-1beta and cAMP in rat mesangial cells. J Immunol 1998; 160: 4961–4969.

    CAS  PubMed  Google Scholar 

  45. Bacher S, Schmitz ML . The NF-κB pathway as a potential target for autoimmune disease therapy. Curr Pharm Des 2004; 10: 2827–2837.

    Article  CAS  PubMed  Google Scholar 

  46. Dale E, Davis M, Faustman DL . A role for transcription factor NF-kappaB in autoimmunity: possible interactions of genes, sex, and the immune response. Adv Physiol Educ 2006; 30: 152–158.

    Article  PubMed  Google Scholar 

  47. Kurylowicz AA . The role of nuclear factor-kappaB in the development of autoimmune diseases: a link between genes and environment. Acta biochim pol 2008; 55: 629–647.

    CAS  PubMed  Google Scholar 

  48. Fu Y, Xie C, Yan M, Li Q, Joh JW, Lu C et al. The lipopolysaccharide-triggered mesangial transcriptome: evaluating the role of interferon regulatory factor-1. Kidney Int 2005; 67: 1350–1361.

    Article  CAS  PubMed  Google Scholar 

  49. Giri S, Nath N, Smith B, Viollet B, Singh AK, Singh I . 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside inhibits proinflammatory response in glial cells: a possible role of AMP-activated protein kinase. J Neurosci 2004; 24: 479–487.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Zhao X, Zmijewski JW, Lorne E, Liu G, Park YJ, Tsuruta Y et al. Activation of AMPK attenuates neutrophil proinflammatory activity and decreases the severity of acute lung injury. Am J Physiol Lung Cell Mol Physiol 2008; 295: L497–L504.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Barati MT, Rane MJ, Klein JB, McLeish KR . A proteomic screen identified stress-induced chaperone proteins as targets of Akt phosphorylation in mesangial cells. J Proteome Res 2006; 5: 1636–1646.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Nagai K, Matsubara T, Mima A, Sumi E, Kanamori H, Iehara N et al. Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in diabetic nephropathy. Kidney Int 2005; 68: 552–561.

    Article  CAS  PubMed  Google Scholar 

  53. Fayard E, Tintignac LA, Baudry A, Hemmings BA . Protein kinase B/Akt at a glance. J Cell Sci 2005; 118: 5675–5678.

    Article  CAS  PubMed  Google Scholar 

  54. Yang J, Cron P, Good VM, Thompson V, Hemmings BA, Barford D . Crystal structure of an activated Akt/protein Kinase B ternary complex with GSK3-peptide and AMP-PNP. Nat Struct Mol Biol 2002; 9: 940–944.

    Article  CAS  Google Scholar 

  55. Wu T, Mohan C . The AKT axis as a therapeutic target in autoimmune diseases. Endoc Metab Immune Disord Drug Targets 2009; 9: 145–150.

    Article  CAS  Google Scholar 

  56. Zhang T, Yang D, Fan Y, Xie P, Li H . Epigallocatechin-3-gallate enhances ischemia/reperfusion-induced apoptosis in human umbilical vein endothelial cells via AKT and MAPK pathways. Apoptosis 2009; 14: 1245–1254.

    Article  CAS  PubMed  Google Scholar 

  57. Ahn HY, Xu Y, Davidge ST . Epigallocatechin-3-O-gallate inhibits TNFalpha-induced monocyte chemotactic protein-1 production from vascular endothelial cells. Life Sci 2008; 82: 964–968.

    Article  CAS  PubMed  Google Scholar 

  58. Ohga N, Hida K, Hida Y, Muraki C, Tsuchiya K, Matsuda K et al. Inhibitory effects of epigallocatechin-3 gallate, a polyphenol in green tea, on tumor-associated endothelial cells and endothelial progenitor cells. Cancer Sci 2009; 100: 1963–1970.

    Article  CAS  PubMed  Google Scholar 

  59. Navarro-Peran E, Cabezas-Herrera J, Sanchezp-del-Campo L, Garcia-Canovas F, Rodriguez-Lopez N . The anti-inflammatory and anti-cancer properties of epigallocatechin-3-gallate are mediated by folate cycle disruption, adenosine release and NF-κB suppression. Inflamm Res 2008; 57: 1–7.

    Article  Google Scholar 

  60. Kim JM, Kim HI, Chung J, Jeong TS, Park HR . (−)-Epigallocatechin-3-gallate (EGCG) increases the viability of serum-starved A549 cells through its effect on Akt. Am J Chin Med 2009; 37: 723–734.

    Article  CAS  PubMed  Google Scholar 

  61. Lin SK, Chang HH, Chen YJ, Wang CC, Galson DL, Hong CY et al. Epigallocatechin-3-gallate diminishes CCL2 expression in human osteoblastic cells via up-regulation of phosphatidylinositol 3-kinase/Akt/Raf-1 interaction: a potential therapeutic benefit for arthritis. Arthritis Rheum 2008; 58: 3145–3156.

    Article  CAS  PubMed  Google Scholar 

  62. Weichhart T, Säemann MD . The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications. Ann Rheum Dis 2008; 67: iii70–iii74.

    Article  CAS  PubMed  Google Scholar 

  63. Xing B, Xin T, Hunter R, Bing G . Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt. J Neuroinflammation 2008; 5: 4.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Di Cristofano A, Kotsi P, Peng YF, Cordon-Cardo C, Elkon KB, Pandolfi PP . Impaired Fas response and autoimmunity in Pten+/− mice. Science 1999; 285: 2122–2125.

    Article  CAS  PubMed  Google Scholar 

  65. R-Borlado L, Redondo C, Alvarez B, Jimenez C, Criado LM, Flores J et al. Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo. FASEB J 2000; 14: 895–903.

    Article  Google Scholar 

  66. Wei CC, Chang MS . A novel transcript of mouse interleukin-20 receptor acts on glomerular mesangial cells as an aggravating factor in lupus nephritis. Genes Immun 2008; 9: 668–679.

    Article  CAS  PubMed  Google Scholar 

  67. Barber DF, Bartolomé A, Hernandez C, Flores JM, Redondo C, Fernandez-Arias C et al. PI3K-gamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat Med 2005; 11: 933–935.

    Article  CAS  PubMed  Google Scholar 

  68. Wu T, Qin X, Kurepa Z, Kumar KR, Liu K, Kanta H et al. Shared signaling networks active in B cells isolated from genetically distinct mouse models of lupus. J Clin Invest 2007; 117: 2186–2196.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Marone R, Cmiljanovic V, Giese B, Wymann MP . Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta 2008; 1784: 159–185.

    Article  CAS  PubMed  Google Scholar 

  70. Lui S, Yung S, Tsang R, Zhang F, Chan K, Tam S et al. Rapamycin prevents the development of nephritis in lupus-prone NZB/W F1 mice. Lupus 2008; 17: 305–313.

    Article  CAS  PubMed  Google Scholar 

  71. Reddy P, Legault H, Sypek J, Collins M, Goad E, Goldman S et al. Mapping similarities in mTOR pathway perturbations in mouse lupus nephritis models and human lupus nephritis. Arthritis Res Ther 2008; 10: R127.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Ramos-Barron A, Pinera-Haces C, Gomez-Alamillo C, Santiuste-Torcida I, Ruiz J, Buelta-Carrillo L et al. Prevention of murine lupus disease in (NZBxNZW)F1 mice by sirolimus treatment. Lupus 2007; 16: 775–781.

    Article  CAS  PubMed  Google Scholar 

  73. Warner L, Adams L, Sehgal S . Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus. Arthritis Rheum 1994; 37: 289–297.

    Article  CAS  PubMed  Google Scholar 

  74. Hochegger K, Jansky GL, Soleiman A, Wolf AM, Tagwerker A, Seger C et al. Differential effects of rapamycin in anti-GBM glomerulonephritis. J Am Soc Nephrol 2008; 19: 1520–1529.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Vogelbacher R, Wittmann S, Braun A, Daniel C, Hugo C . The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat. Transplantation 2007; 84: 1492–1499.

    Article  CAS  PubMed  Google Scholar 

  76. Letavernier E, Bruneval P, Mandet C, Van Huyen JP, Peraldi MN, Helal I et al. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2007; 2: 326–333.

    Article  CAS  PubMed  Google Scholar 

  77. Salcedo R, Ponce ML, Young HA, Wasserman K, Ward JM, Kleinman HK et al. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000; 96: 34–40.

    CAS  PubMed  Google Scholar 

  78. Yoshida M, Xia Y . Heat Shock Protein 90 as an endogenous protein enhancer of inducible nitric-oxide synthase. J Biol Chem 2003; 278: 36953–36958.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This project was funded by grants from the Harvey Peters Foundation (Peairs), Arthritis Foundation (Reilly) and the NIH/NIAD grant 1R15A1072756 (Reilly). The authors would also like to acknowledge the laboratory assistance of Krystina Cocco, Sarah Muse, Nicole Regna and David Fulbrook, in addition to Melissa Makris for flow cytometry.

Author information

Authors and Affiliations

  1. Virginia College of Osteopathic Medicine, Blacksburg, VA, USA

    Abigail Peairs & Christopher M Reilly

  2. Department of Biomedical Sciences and Pathobiology, Virginia-Maryland Regional College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA

    Rujuan Dai & Christopher M Reilly

  3. Department of Biological Sciences, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA

    Lu Gan & Liwu Li

  4. Department of Mechanical Engineering, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA

    Samuel Shimp & M Nichole Rylander

Authors
  1. Abigail Peairs
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rujuan Dai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lu Gan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Samuel Shimp
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Nichole Rylander
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Liwu Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Christopher M Reilly
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Abigail Peairs.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Peairs, A., Dai, R., Gan, L. et al. Epigallocatechin-3-gallate (EGCG) attenuates inflammation in MRL/lpr mouse mesangial cells. Cell Mol Immunol 7, 123–132 (2010). https://doi.org/10.1038/cmi.2010.1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cmi.2010.1

Keywords

This article is cited by

Search

Advanced search

Quick links